The Zabalafin Platform: Fighting Many Diseases in Many Ways

Alphyn’s Zabalafin Platform (AB-101 Platform) is a single source botanical with multiple bioactive compounds to produce therapeutics with multiple mechanisms of action. This enables Alphyn’s therapeutics to attack an individual disease in multiple ways and attack many different diseases. With the power of the Zabalafin Platform, Alphyn is establishing a deep product pipeline of potentially more effective and safer therapeutics for patients suffering from skin diseases with few or sub-optimal treatment options.

Safer, Cost-Efficient, & Faster

Based on the clinical success of zabalafin hydrogel (AB-101a) to date, the Zabalafin Platform offers the potential for safer products with fewer side effects and excellent patient tolerability. Drugs using the Zabalafin Platform have the possibility of advancing from the clinic to the patient faster and more cost-efficiently than standard drugs

A Robust Drug Raw Material Supply Program

Alphyn is building a robust drug raw material supply program to ensure abundant supply of consistent and reproducible drug substance raw material that meets FDA and other global health authority regulatory requirements and supports our therapeutic pipeline. Our current drug raw material supply can already sustain more than $1 billion in annual revenue and ongoing expansion will support greater sales volumes.